Eli Lilly is set to pay InnoCare Pharma up to $3.35 billion to discover and develop compounds against upwards of five undisclosed targets.
News|Articles|September 24, 2026
The Healthcare Insight Gap: Why Generic AI Falls Short and What Healthcare Marketers Need Instead
Author(s)LiveWorld
How Human-Led, AI-Powered systems designed specifically for healthcare turn data overload into decision-ready insight. Healthcare marketers are flooded with data, from patient conversations and HCP feedback to social listening, CRM activity, and market signals, yet actionable insights remain difficult to uncover. This eBook explores why generic AI often falls short in healthcare and shows how a Human-Led, AI-Powered approach can turn complex data into trusted, decision-ready intelligence.
Related to this article
FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes.
Why self-reported data fails clinical trials — and how RWD and AI fix enrollment accuracy before the first patient is dosed.
Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures.
EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real barrier to enterprise AI adoption in life sciences, and Novo Nordisk's CEO says he's open to a direct NYSE listing.
Novo Nordisk CEO Mike Doustdar says he's open to a direct NYSE listing that would replace the company's ADR structure.
Market access is now too complex for historical analogues — and AI is the only tool that can model what comes next.
Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential.
Trending on PharmExec
1
Pharmaceutical Executive Daily: Mike Doustdar Open to Direct Listing for Novo Shares
2
Nine European Drugmakers Warn the Continent Risks Losing the Pharma Investment Race: Report
3
Shaping the Future of Market Access: Q&A with Jen Norton
4
From Experimentation to Execution: Strategic AI Adoption and Clinical Data Harmonization in Life Sciences
5